Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 14/20 | 0.60 |
| ▸ | APOB | P04114 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207411 | 0.90 | MTTP (0.60) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8206848 | 0.87 | MTTP (0.56) | MTTPAPOBKDM4ESMO | |
| SCHEMBL8208880 | 0.87 | MTTP (0.56) | MTTPAPOBKDM4ESMO | |
| SCHEMBL8208392 | 0.86 | MTTP (0.58) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8199895 | 0.85 | APOB (0.57) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8210365 | 0.84 | MTTP (0.53) | MTTPAPOBKDM4ESMO | |
| SCHEMBL8201225 | 0.82 | MTTP (0.61) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8211067 | 0.82 | MTTP (0.61) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8213608 | 0.81 | MTTP (0.60) | MTTPAPOBKDM4ESMOGAA | |
| SCHEMBL8209080 | 0.81 | MTTP (0.56) | MTTPAPOBKDM4ESMOGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268404-B1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | disclosed |
| US-7202275-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | WARNER LAMBERT COMPANY LLC (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1199071-B1 | Use of an estrogen agonist/antagonist for improving vascular health | PFIZER PROD INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1297833-B1 | Indole carboxylic acids as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1148054-B1 | Thyroid receptor ligands | PFIZER PROD INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-6960604-B2 | Thyroid receptor ligands | PFIZER INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | disclosed |
| US-6924310-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| US-20010051645-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2001-12-13 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | MTTP 542/4885APOB 91/4885KDM4E 3949/4885 |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | MTTP 542/4885APOB 91/4885KDM4E 3949/4885 |
| US-20010051645-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | MTTP 1007/4885APOB 630/4885KDM4E 3595/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | MTTP 332/4885APOB 1275/4885KDM4E 3587/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | MTTP 690/4885APOB 90/4885KDM4E 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.